Developer docs
API playgroundTry for free, no card

Search company profiles

Interius BioTherapeutics

Full company profile

uuid00004tb

Namestring
Interius BioTherapeutics
Legal namestring
Interius BioTherapeutics, Inc.
Websiteurl
interiusbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Interius BioTherapeutics was a clinical-stage biotechnology company founded in 2019 as a University of Pennsylvania spinout, developing in vivo CAR T-cell therapies for hematologic malignancies and other diseases. The company's core technology is a cell-specific gene delivery platform that reprograms immune cells directly inside the patient's body via a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy that characterize conventional CAR-T treatments. Its lead candidate, INT2104, was the first in vivo cell therapy to enter Phase I human clinical trials for B-cell malignancies, with additional research directed at autoimmune disease indications.

The company operated as a pre-commercial, venture-backed biotech, generating no product revenue and funding its R&D through institutional equity rounds totaling nearly $100 million since inception. In August 2025, Interius was acquired by Gilead Sciences' subsidiary Kite Pharma for $350 million in cash, and its operations were integrated into Kite's cell therapy research team in Philadelphia. The acquisition provided Kite with a next-generation in vivo platform intended to complement its existing ex vivo CAR-T franchise (Yescarta and Tecartus) and potentially simplify the cell therapy treatment paradigm.

Short descriptiontext

Interius BioTherapeutics is a Philadelphia-based, clinical-stage biotechnology company (acquired by Kite Pharma in August 2025) developing in vivo CAR T-cell therapies that reprogram immune cells inside patients via a single IV infusion for hematologic malignancies.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vivo gene therapy, CAR T-cell therapy, cell-specific gene delivery, cancer cell therapy, biopharmaceutical development
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy / Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Funding / R&D Stage
TypeLicensing Royalties
Description

Prior to acquisition, Interius operated as a pre-commercial biotech company developing novel gene delivery technology, funded entirely through venture capital and institutional investments. The company raised nearly $100 million since inception in 2019 through Series A and subsequent financing rounds.

biospace.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Interius BioTherapeutics develops an in vivo CAR T-cell therapy platform that reprograms patients' immune cells directly inside the body through a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy. The company's lead clinical candidate, INT2104, is being evaluated in Phase I trials for B-cell malignancies, with the platform also being explored for autoimmune disease applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First in vivo CAR T-cell therapy to enter human clinical trials (Phase I)
+2 more records
Product overview1 text field

Interius BioTherapeutics is developing an in vivo CAR T-cell therapy platform that reprograms immune cells directly inside patients' bodies without complex lab manipulation. The company's lead candidate INT2104 is in Phase I clinical trials for B-cell malignancies. The platform technology enables cell-specific gene delivery and eliminates the need for preconditioning chemotherapy and complex cell processing that characterizes traditional CAR-T treatments.

Product and service1 record
1INT2104
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Gilead's subsidiary Kite Pharma acquired Interius BioTherapeutics for $350 million to integrate its in vivo CAR T-cell therapy platform into Kite's research operations. The acquisition positions Interius's technology within Kite's global cell therapy infrastructure and established commercial network.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb (Breyanzi, Abecma)
TypeBroad incumbent
Description

Approved CAR-T franchises (Breyanzi for lymphoma, Abecma for myeloma) directly competing in the same hematologic malignancy space as INT2104.

TypeBroad incumbent
Description

Parent company since August 2025 and the incumbent leader in autologous CAR-T with Yescarta and Tecartus. Directly comparable as a CAR-T developer targeting B-cell malignancies with established commercial infrastructure.

TypeDirect peer
Description

Closest direct competitor — also developing in vivo CAR-T cell therapy platforms using redirected delivery of genetic payloads to immune cells, pursuing the same simplified modality that Interius pioneered.

TypeBroad incumbent
Description

Approved autologous CAR-T (Kymriah) for B-cell malignancies — the incumbent therapeutic modality Interius aims to disrupt with its in vivo approach.

TypeEmerging player
Description

Developing allogeneic CAR-T cell therapies with CRISPR-edited immune cells — competing in the next-generation CAR-T space and pursuing off-the-shelf alternatives to autologous approaches.

TypeEmerging player
Description

Pioneer of allogeneic ("off-the-shelf") CAR-T therapies targeting similar B-cell malignancies with the same goal of simplifying access to cell therapy.

TypeEmerging player
Description

Gene-editing-based cell therapy company developing CASGEVY (with Vertex) and allogeneic CAR-T candidates — comparable in applying novel gene engineering to immune cell therapy.

TypeEmerging player
Description

Developing in vivo gene editing and allogeneic CAR-T therapies using ARCUS platform — directly comparable as a developer of in vivo genome editing approaches to cell therapy.

TypeEmerging player
Description

iPSC-derived off-the-shelf NK and T-cell therapies for oncology and autoimmune disease — comparable as a next-generation cell therapy developer pursuing simplified treatment paradigms.

TypeEmerging player
Description

Developer of Abecma (with BMS) and pipeline of next-generation cell therapies for hematologic malignancies — overlapping target indications and cell therapy modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Interius BioTherapeutics

Cell Therapy / Cancer Immunotherapyinteriusbio.com

Interius BioTherapeutics is a Philadelphia-based, clinical-stage biotechnology company (acquired by Kite Pharma in August 2025) developing in vivo CAR T-cell therapies that reprogram immune cells inside patients via a single IV infusion for hematologic malignancies.

What Interius BioTherapeutics does

Interius BioTherapeutics was a clinical-stage biotechnology company founded in 2019 as a University of Pennsylvania spinout, developing in vivo CAR T-cell therapies for hematologic malignancies and other diseases. The company's core technology is a cell-specific gene delivery platform that reprograms immune cells directly inside the patient's body via a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy that characterize conventional CAR-T treatments. Its lead candidate, INT2104, was the first in vivo cell therapy to enter Phase I human clinical trials for B-cell malignancies, with additional research directed at autoimmune disease indications.

The company operated as a pre-commercial, venture-backed biotech, generating no product revenue and funding its R&D through institutional equity rounds totaling nearly $100 million since inception. In August 2025, Interius was acquired by Gilead Sciences' subsidiary Kite Pharma for $350 million in cash, and its operations were integrated into Kite's cell therapy research team in Philadelphia. The acquisition provided Kite with a next-generation in vivo platform intended to complement its existing ex vivo CAR-T franchise (Yescarta and Tecartus) and potentially simplify the cell therapy treatment paradigm.

Interius BioTherapeutics firmographics

Firmographics
Name
Interius BioTherapeutics
Legal name
Interius BioTherapeutics, Inc.
Website
https://interiusbio.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
11–50 employees
Short description
Interius BioTherapeutics is a Philadelphia-based, clinical-stage biotechnology company (acquired by Kite Pharma in August 2025) developing in vivo CAR T-cell therapies that reprogram immune cells inside patients via a single IV infusion for hematologic malignancies.
Ownership category
akta.pro rank

Interius BioTherapeutics industry classification

Industry
Product category
Cell Therapy / Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • In vivo gene therapy
  • CAR T-cell therapy
  • Cell-specific gene delivery
  • Cancer cell therapy
  • Biopharmaceutical development

Where Interius BioTherapeutics is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Interius BioTherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Venture Funding / R&D Stage: Prior to acquisition, Interius operated as a pre-commercial biotech company developing novel gene delivery technology, funded entirely through venture capital and institutional investments. The company raised nearly $100 million since inception in 2019 through Series A and subsequent financing rounds.

Go-to-market motion1 record

Interius BioTherapeutics product offering

Product offering

Core offering

Interius BioTherapeutics develops an in vivo CAR T-cell therapy platform that reprograms patients' immune cells directly inside the body through a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy. The company's lead clinical candidate, INT2104, is being evaluated in Phase I trials for B-cell malignancies, with the platform also being explored for autoimmune disease applications.

Product overview

Interius BioTherapeutics is developing an in vivo CAR T-cell therapy platform that reprograms immune cells directly inside patients' bodies without complex lab manipulation. The company's lead candidate INT2104 is in Phase I clinical trials for B-cell malignancies. The platform technology enables cell-specific gene delivery and eliminates the need for preconditioning chemotherapy and complex cell processing that characterizes traditional CAR-T treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • INT2104

Quantifiable outcome

  • First in vivo CAR T-cell therapy to enter human clinical trials (Phase I)
  • +2 more outcomes

Companies that use Interius BioTherapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Interius BioTherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Interius BioTherapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gilead Sciences / Kite PharmaflagshipStrategic or Co-development Partner · 21 August 2025Gilead's subsidiary Kite Pharma acquired Interius BioTherapeutics for $350 million to integrate its in vivo CAR T-cell therapy platform into Kite's research operations. The acquisition positions Interius's technology within Kite's global cell therapy infrastructure and established commercial network.

Scale indicators6 records

Recent moves7 records

Expansion highlights2 records

Interius BioTherapeutics competitors and assessment

Company assessment

Broad incumbents

  • Bristol Myers Squibb (Breyanzi, Abecma): Approved CAR-T franchises (Breyanzi for lymphoma, Abecma for myeloma) directly competing in the same hematologic malignancy space as INT2104.
  • Kite Pharma (Gilead Sciences): Parent company since August 2025 and the incumbent leader in autologous CAR-T with Yescarta and Tecartus. Directly comparable as a CAR-T developer targeting B-cell malignancies with established commercial infrastructure.
  • Novartis (Kymriah): Approved autologous CAR-T (Kymriah) for B-cell malignancies — the incumbent therapeutic modality Interius aims to disrupt with its in vivo approach.

Direct peers

  • Umoja Biopharma: Closest direct competitor — also developing in vivo CAR-T cell therapy platforms using redirected delivery of genetic payloads to immune cells, pursuing the same simplified modality that Interius pioneered.

Emerging players

  • Caribou Biosciences: Developing allogeneic CAR-T cell therapies with CRISPR-edited immune cells — competing in the next-generation CAR-T space and pursuing off-the-shelf alternatives to autologous approaches.
  • Allogene Therapeutics: Pioneer of allogeneic ("off-the-shelf") CAR-T therapies targeting similar B-cell malignancies with the same goal of simplifying access to cell therapy.
  • CRISPR Therapeutics: Gene-editing-based cell therapy company developing CASGEVY (with Vertex) and allogeneic CAR-T candidates — comparable in applying novel gene engineering to immune cell therapy.
  • Precision BioSciences: Developing in vivo gene editing and allogeneic CAR-T therapies using ARCUS platform — directly comparable as a developer of in vivo genome editing approaches to cell therapy.
  • Fate Therapeutics: iPSC-derived off-the-shelf NK and T-cell therapies for oncology and autoimmune disease — comparable as a next-generation cell therapy developer pursuing simplified treatment paradigms.
  • 2seventy bio: Developer of Abecma (with BMS) and pipeline of next-generation cell therapies for hematologic malignancies — overlapping target indications and cell therapy modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Interius BioTherapeutics social profiles

Digital presence

Interius BioTherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Interius BioTherapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Interius BioTherapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Interius BioTherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interius BioTherapeutics

What does Interius BioTherapeutics do?

Interius BioTherapeutics develops an in vivo CAR T-cell therapy platform that reprograms patients' immune cells directly inside the body through a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy. The company's lead clinical candidate, INT2104, is being evaluated in Phase I trials for B-cell malignancies, with the platform also being explored for autoimmune disease applications.

Is Interius BioTherapeutics a public or private company?

Interius BioTherapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Interius BioTherapeutics founded?

Interius BioTherapeutics was founded in 2019. It employs 11 to 50 people.

Where is Interius BioTherapeutics based?

Interius BioTherapeutics is headquartered in Philadelphia, United States, in the North America region.

How does Interius BioTherapeutics make money?

One revenue line is on record: venture Funding / R&D Stage.

Who are Interius BioTherapeutics's main competitors?

Broad incumbents on record are Bristol Myers Squibb (Breyanzi, Abecma), Kite Pharma (Gilead Sciences) and Novartis (Kymriah). Umoja Biopharma is listed as a direct peer. Emerging players are Caribou Biosciences, Allogene Therapeutics, CRISPR Therapeutics, Precision BioSciences, Fate Therapeutics and 2seventy bio.

Does Interius BioTherapeutics have an API?

No public API is recorded for Interius BioTherapeutics.

What industry is Interius BioTherapeutics in?

Interius BioTherapeutics's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Phirda双靶点 CAR-T:细胞疗法的下一个价值周期CD20/CD19 dual-target CAR-T therapies are advancing to address antigen escape, with Miltenyi's zamto-cel seeking EMA approval and C-CAR039 showing 5-year PFS of 60.1 months. Global MNCs and Chinese firms are investing, and regulatory policies support these products.European BiotechnologyCan Sanofi buy its way into in vivo CAR-T?Sanofi published preclinical data showing its in vivo CAR-T platform can deliver mRNA-encoded CARs to CD8+ T cells, generating functional CAR-T cells that inhibit tumor growth. The platform combines mRNA payloads, lipid nanoparticles, and targeted guidance from acquired companies, though CAR expression remains transient. The results are confined to hematological models, with broader applications pending.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.Labiotech.euIn vivo CAR-T gains momentum as big pharma bets billionsBig pharma is shifting toward in vivo CAR-T therapies, with Lilly planning a $7B acquisition of Kelonia Therapeutics. Other deals include AstraZeneca's $1B purchase of EsoBiotec and Gilead's $350M buy of Interius BioTherapeutics. The shift aims to overcome manufacturing and cost barriers of ex vivo CAR-T.FiercePharmaWith ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision loomsAfter recalibrating its production strategy in the late 2010s, Gilead Sciences' Kite Pharma is preparing for the potential approval of its next-generation multiple myeloma cell therapy anito-cel later this year, with commercial-scale manufacturing readiness at its Frederick, Maryland facility. Kite has built the world's largest dedicated in-house cell therapy manufacturing network, including facilities in the U.S., Netherlands, and a distribution center in Japan, and has internalized viral vector production to mitigate supply shortfalls. The company is also pursuing in vivo CAR-T technologies through the $350 million acquisition of Interius BioTherapeutics and a $120 million upfront deal with China biotech Pregene, aiming to simplify manufacturing and expand patient access.PhirdaMNC 超百亿美元卡位的体内 CAR-T 有哪些新期待?Major pharmaceutical companies have spent over $10 billion on in vivo CAR-T platforms, with clinical data emerging in 2025. LNP-based therapies target autoimmune diseases, while lentiviral approaches focus on tumors, with several candidates entering clinical trials.openPR.comCell and Gene Therapy Manufacturing Services Market is set to reach US$ 23.42 Billion by 2033, at a strong CAGR of 15.2%, North America leads the market with 45.47% of market share | Major Players:- CDataM Intelligence released a market report projecting the Cell and Gene Therapy Manufacturing Services Market to grow from US$6.61 billion in 2024 to US$23.42 billion by 2033, representing a CAGR of 15.2%, with North America holding the largest market share at 45.47%. The report highlights significant M&A activity including AbbVie's $2.1 billion acquisition of Capstan Therapeutics and Kite's (Gilead) $350 million acquisition of Interius BioTherapeutics, both in August 2025. Key growth drivers cited include over 1,500 registered CGT clinical trials and 65% of advanced therapy production being outsourced to CDMOs.Beacon-IntelligenceIn Vivo CAR T Cell TherapiesThis article provides a comprehensive scientific review of in vivo CAR T-cell therapy, a next-generation approach that delivers genetic instructions to program T cells inside the patient's body, potentially reducing treatment timelines from weeks to days compared to current ex vivo methods requiring apheresis and external manufacturing. Two clinical programs are highlighted as pioneering this field: Capstan Therapeutics' CPTX2309 (anti-CD19 tLNP-mRNA for autoimmunity) and Interius BioTherapeutics' INT2104/INVISE (CD20-targeted for oncology, the first in vivo CAR gene therapy trial cleared in Europe by the Paul Ehrlich Institute). The article outlines key opportunities including reduced costs, broader access, and new indications in autoimmunity and fibrosis, alongside challenges such as targeting specificity, safety management, and immunogenicity concerns that the field must address as it advances through 2025.LinkedInInvesting in Precision Medicine: VC | PE | M&A - August Round-Up 2025In August 2025, the biotech, pharma, and health tech sectors experienced active M&A deals, fundraisings, and private equity investments. Major acquisitions included Gilead’s $350 million purchase of Interius BioTherapeutics and MannKind’s acquisition of scPharmaceuticals for up to $360 million. The event highlights a focus on oncology, cell therapy, and next-generation assets within the industry.Pulse 2.0Kite To Buy Interius BioTherapeutics In $350 Million DealKite, a Gilead company, agreed to acquire Interius BioTherapeutics for $350 million in cash. The deal targets in vivo CAR T cell therapy, which can be delivered via a single IV infusion without preconditioning chemotherapy. The acquisition is expected to modestly reduce Gilead's 2025 earnings per share by $0.23 to $0.25.